Poor antibody validation is a challenge in biomedical research: A case study for detection of c-FLIP

Apoptosis

Volumn 18, Issue 10, 2013, Pages 1154-1162

  Bucur, Octavian ^a,b   Pennarun, Bodvael ^a   Stancu, Andreea Lucia ^a   Nadler, Monica ^a   Muraru, Maria Sinziana ^a   Bertomeu, Thierry ^a   Khosravi Far, Roya ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

Antibodies; Apoptosis; c FLIP; Methods; Technologies

Indexed keywords

FLICE INHIBITORY PROTEIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL CELL; ANTIBODY DETECTION; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; HUMANS; MICE; RABBITS;

EID: 84885392605     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0880-0     Document Type: Article

References (52)

1. Francia G, Kerbel RS (2010) Raising the bar for cancer therapy models. Nat Biotechnol 28(6):561-562
2. Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483(7391):531-533
3. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1(9):683-695
4. Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 3(4):279-296
5. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280(15):14507-14513
6. Oztürk S, Schleich K, Lavrik IN (2012) Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions. Exp Cell Res 318(11):1324-1331
7. Ewald F, Ueffing N, Brockmann L, Hader C, Telieps T, Schuster M, Schulz WA, Schmitz I (2011) The role of c-FLIP splice variants in urothelial tumours. Cell Death Dis 2:e245
8. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN et al (2013) Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 332(2):194-201
9. Bucur O, Ray S, Bucur MC, Almasan A (2006) APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11:1549-1568
10. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF (2004) Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64(19):7086-7091
11. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I et al (2007) c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 51(2):150-156
12. Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y, Chen CC, Wang LJ, Chang YS (2010) The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ 17(9):1463-1473
13. Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, Lu J, Ma Q (2009) Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 20(28):24
14. Plati J, Bucur O, Khosravi-Far R (2008) Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 104(4):1124-1149
15. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25(6):838-848
16. Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G et al (2010) c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity. Cell Death Differ 17(12):1908-1916
17. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R et al (2011) FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523-526
18. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C et al (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471(7338):363-367
19. Peter ME (2011) Programmed cell death: apoptosis meets necrosis. Nature 471(7338):310-312
20. Schmidt M, Hupe M, Endres N, Raghavan B, Kavuri S, Geserick P et al (2010) The contact allergen nickel sensitizes primary human endothelial cells and keratinocytes to TRAIL-mediated apoptosis. J Cell Mol Med 14(6B):1760-1776
21. Ding J, Polier G, Köhler R, Giaisi M, Krammer PH, Li-Weber M (2012) Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem 287(1):641-649
22. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K et al (2012) Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 19(8):1317-1327
23. Wang X, Viswanath R, Zhao J, Tang S, Hewlett I (2010) Changes in the level of apoptosis-related proteins in Jurkat cells infected with HIV-1 versus HIV-2. Mol Cell Biochem 337(1-2):175-183
24. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA (2002) Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123(1):168-174
25. Haimerl F, Erhardt A, Sass G, Tiegs G (2009) Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 284(1):495-504
26. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C et al (2008) Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68(21):8687-8694
27. Stagni V, di Bari MG, Cursi S, Condò I, Cencioni MT, Testi R et al (2008) ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 111(2):829-837
28. Ferrarini M, Delfanti F, Gianolini M, Rizzi C, Alfano M, Lazzarin A et al (2008) NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short-versus long-term cultured human gamma delta lymphocytes. J Immunol 181(9):5857-5864
29. Chandrasekaran Y, McKee CM, Ye Y, Richburg JH (2008) Influence of TRP53 status on FAS membrane localization, CFLAR (c-FLIP) ubiquitinylation, and sensitivity of GC-2spd (ts) cells to undergo FAS-mediated apoptosis. Biol Reprod 74(3):560-568
30. Chandrasekaran Y, Richburg JH (2005) The p53 protein influences the sensitivity of testicular germ cells to mono-(2-ethylhexyl) phthalate-induced apoptosis by increasing the membrane levels of Fas and DR5 and decreasing the intracellular amount of c-FLIP. Biol Reprod 72(1):206-213
31. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10):4055-4062
32. Vesely DL, Hoffman B, Liebermann DA (2007) Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells. Oncogene 26(21):3041-3050
33. Schuster C, Malinowsky K, Liebmann S, Berg D, Wolff C, Tran K et al (2012) Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues. Histopathology 60(6B):E37-E50
34. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR et al (2012) miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 55(2):465-475
35. Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ (2008) BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 7(8):2339-2347
36. Vesely ED, Heilig CW, Brosius FC 3rd (2009) GLUT1-induced cFLIP expression promotes proliferation and prevents apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 297(3):C759-C765
37. Guicciardi ME, Bronk SF, Werneburg NW, Gores GJ (2007) cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am J Physiol Gastrointest Liver Physiol 292(5):G1337-G1346
38. Guerreiro-Cacais AO, Levitskaya J, Levitsky V (2010) B cell receptor triggering sensitizes human B cells to TRAIL-induced apoptosis. J Leukoc Biol 88(5):937-945
39. Järvinen K, Hotti A, Santos L, Nummela P, Hölttä E (2011) Caspase-8, c-FLIP, and caspase-9 in c-Myc-induced apoptosis of fibroblasts. Exp Cell Res 317(18):2602-2615
40. Jeudy S, Wardrop KE, Alessi A, Dominov JA (2011) Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy. PLoS One 6(8):e22369
41. Jang JH, Moritz W, Graf R, Clavien PA (2008) Preconditioning with death ligands FasL and TNF-alpha protects the cirrhotic mouse liver against ischaemic injury. Gut 57(4):492-499
42. Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U et al (2010) The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest 120(1):343-356
43. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010) Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285(25):19162-19172
44. Singh A, Ye M, Bucur O, Zhu S, Tanya Santos M, Rabinovitz I et al (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21(6):1140-1152
45. Ray S, Bucur O, Almasan A (2005) Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10(6):1411-1418
46. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D et al (2007) Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 142(2):281-286
47. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715
48. Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10(9):712
49. Mullard A (2011) Reliability of 'new drug target' claims called into question. Nat Rev Drug Discov 10(9):643-644
50. Lavrik IN, Krammer PH (2012) Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 19(1):36-41
51. Jensen BC, Swigart PM, Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379(4):409-412
52. Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN (2004) Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem 52(10):1367-1376